
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics Inc. presents an attractive current valuation with potential for significant upside, as indicated by recent net present value analyses reflecting an increase in projected share price. The company's lead program, Stenoparib, demonstrates promising clinical benefits, notably a median overall survival exceeding 25 months for patients involved in its Phase 2 trial, establishing its efficacy for those with limited treatment options. Furthermore, the integration of proprietary Drug Response Predictor technology enhances patient selection and clinical outcomes, positioning the company favorably within the oncology therapeutic landscape.
Bears say
Allarity Therapeutics Inc reported a net loss of $2.8 million, resulting in an EPS of $(0.19), which is marginally better than estimates but still indicative of financial challenges. The company faces significant risks that may impede its growth, including balance sheet and liquidity issues, potential failures in clinical trials, and difficulties in gaining regulatory approvals. Additionally, ongoing market dynamics and competition further compound the uncertainty surrounding the commercial viability of its lead program, stenoparib, contributing to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares